For our last Community Spotlight of the year, we want to highlight the courage of Veronica Masters.
Veronica bravely accepted the interview request from CBC to talk about something she — and a number of other HCV-infected individuals — are facing as one of the main barriers to treatment: the cost of treatment. However, they are not only battling the cost of the treatment, they are struggling against access to the treatment:
The cost of a revolutionary medical treatment for hepatitis C is so high that only those with moderate liver disease will have the medicine provided under provincial pharmacare programs. (Carolyn Dunn, CBC News)
In the interview, Veronica details her struggles with the illness, and how she feels about not being “sick-enough” to qualify for funding for treatment.
Our HCV Nurse and General Manager, Shawn Sharma, was also in the interview and spoke on the struggle from the health care provider’s perspective:
“You have to see the patients through the months and they’re just always actively questioning you, ‘Why are you not wanting to treat me?'” Sharma says. “That in and of itself is difficult to kind of go home with every day as a health-care professional.” (CBC News)
The goal of VIDC’s involvement in the interview was to support Veronica is bringing attention to the struggle that a number of HCV-positive individuals face.
The Vancouver Infectious Diseases Centre (VIDC) is now providing Take Home Naloxone Training for individuals using prescribed or diverted opioids. The training educates participants about basic overdose prevention, in addition to how to identify and respond to an opioid overdose, and administer naloxone when appropriate.
What is Naloxone?
Naloxone, also commonly known as Narcan, is an antidote to an opioid overdose. An overdose of opioid drugs such as morphine, heroin, methadone, OxyContin can cause a person’s breathing to slow or stop. Naloxone is an injectable medication that can reverse this so the person can breathe normally and regain consciousness. Naloxone does not work for overdoses such as cocaine, ecstasy, GHB, or alcohol. However, if an overdose involves multiple substances including opioids, naloxone will help by temporarily taking the opioid out the equation.
Who is eligible to receive a Take Home Naloxone Kit?
An individual who has received the training, has a history of illicit opioid use, and a written prescription from a physician is eligible to receive a Take Home Naloxone Kit at no cost. Individuals who don’t use opioids, but know someone who does (eg. Support workers, peers of people who use opioids, family members) are not eligible to receive a kit. They are encouraged to attend the training to learn how to administer naloxone in an emergency situation and how to respond if naloxone isn’t readily available. Morbidity and mortality related to any kind of overdose is significantly reduced when the community has an increased awareness of how to mitigate risks, recognize, and respond appropriately in a timely manner.
For World AIDS Day 2015, we at VIDC quietly remembered our friends who have lost their lives to AIDS and those who are winning their battle with HIV. The whole day was quiet, a little solemn, but also mostly hopeful — our battle with HIV has come a long way in the past couple of decades.
If you’re looking to brush up on your hepatitis C knowledge and be updated on progress made in the medical research around the virus, then this resource is for you.
The American Journal of Medicine (AJM) Description: “The “Green Journal” publishes original clinical research of interest to physicians in internal medicine, both in academia and community-based practice. The American Journal of Medicine is the official journal of the Alliance for Academic Internal Medicine, a prestigious group comprised of chairs of departments of internal medicine at more than 125 medical schools across the country. Each issue carries useful reviews as well as seminal articles of immediate interest to the practicing physician, including peer-reviewed, original scientific studies that have direct clinical significance, and position papers on health care issues, medical education, and public policy. The journal’s ISI factor – the international measure of cited manuscripts and scientific impact – is fourteenth in the world among all general medical journals. The Editor-in-Chief is Joseph Alpert, MD. ” – About Our Hepatitis C Blog
Hepatitis C Blog Description: “The goal of this global hepatitis C blog is to encourage communication and break down communication barriers so clinicians and their supportive care teams can effectively confront the challenges associated with screening, diagnosing, treating, and managing increasing numbers of individuals with hepatitis C. This blog is supported by Elsevier Multimedia Publishing and the American Journal of Medicine (AJM), and serves as a companion to their comprehensive, online, global educational initiative, the AJM Hepatitis C Resource Center (hepcresource.amjmed.com).” – About Our Hepatitis C Blog
AJM Hepatitis C Resource Center Description: “The AJM Hepatitis C Resource Center provides both primary care providers and specialists with continually updated treatment guidelines, and an up-to-date repository of informative, freely-available, full-text articles to encourage effective HCV screening and diagnosis, and to highlight the promise of novel treatment regimens.” – About Our Hepatitis C Blog